Bloomberg
@business
The first word in business news | Watch Live: | Newsletters: | Podcasts:
가입 April 2009
104 팔로잉 중 10.5M 팬
Novo Nordisk will pay as much as $2.6 billion to license an experimental obesity pill from China’s Hengrui, as it seeks to rebuild investor confidence in its future beyond blockbusters Ozempic and Wegovy
더 보기
